The diet ranked last among 38 popular diets evaluated by U.S. News & World Report in its 2016 Best Diets Rankings; one of the raters, dietitian Meridan Zerner said: "We want behavioral changes and dietary changes that are slow and progressive and meaningful." David L. Katz said of the diet: "The grouping [of banned foods] is both random, and rather bizarre from a nutrition perspective. If the idea is good nutrition, cutting out whole grains and legumes is at odds with a boatload of evidence." It was selected as one of the worst health trends for 2013 by Health Magazine.
Glassman is proud of his role in all this, but the system puts him and CrossFit at a very real risk. As the world of CrossFit grows, as more businesses enter and profit, and his share of it becomes smaller, CrossFit's greatest success--gaining mainstream acceptance as exercise and a sport--could turn it generic, like baseball or skiing. "One of our greatest fears is becoming escalator," says Dale Saran, CrossFit's general counsel, referring to what was once a trademarked name brand of Otis Elevator. So, although Glassman keeps the CrossFit business model radically loose and open, he protects the brand name with an iron fist.
When the clock struck midnight, I couldn't wait any longer: I helped myself to a serving of plain white rice. I sat on my couch cross-legged, eating each spoonful with my eyes closed like one of the yogurt commercial ladies. I even smiled. The next day, I ate more gluten-free carbs, like rice and paleo pancakes. I also had wine and tequila, a grain-free liquor option. I didn't get bombed like I was worried about, but I did have a worse-than-usual hangover the next day. The fun night out was worth it, though.
Most of these recipes give us enough dinner for our family and then leftovers for my husband and I (I make a separate lunch for the kids most times). If you both eat normal-sized portions, you would probably be fine to cut it in half and have enough for leftovers. But if you tend to eat larger portions, I’d err on the side of caution and just go with the full amount.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”